Muscle Mass, Quality, and the Menopause: Sex-specific Strategies to Mitigate Sarcopenia in Ageing Populations
University of Nottingham
18 participants
Jul 29, 2024
OBSERVATIONAL
Conditions
Summary
Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those \>65y expected to increase from 18% of the population in 2016, to 26% by 2066. As such, age related muscle mass loss and functional impairments represents one of the largest problems facing the health care services. There is an urgent need to develop strategies to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that the loss in muscle size and strength is different between men and women throughout the aging process. For example, older women have greater levels of physical disability that includes difficulties in walking around the home, getting out of a bed or chair, and eating, compared with men. These sex differences with ageing are unclear, yet the greater levels of physical disability could be the result of the menopause. The menopause describes a change in the sex hormone environment that is a part of normal female ageing. Physical disability can be further enhanced by an increase in body fat during the menopause in the face of decreasing muscle mass. Currently, there is a lack of understanding as to how these changes in body composition occur, with no effective treatments against muscle mass loss. The aims of this project are to increase understanding on how the menopause impacts muscle mass regulation. In addition, the investigators will use novel magnetic resonance imaging (MRI) techniques to map the distribution of newly created fat, and qualitative interviews to better understand how resistance exercise therapy (RET) can be incorporated into the daily lives of postmenopausal women.
Eligibility
Inclusion Criteria5
- Biological woman, 18-65 years of age
- Body mass index (BMI) 18-30 kg/m2
- Non smoker
- Not performing regular resistance type exercise
- Participant is willing and able to give informed consent for participation in the study
Exclusion Criteria17
- A BMI <18 or >39 kg·m-2
- Active cardiovascular disease: uncontrolled hypertension (Blood pressure > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event.
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- Respiratory disease including pulmonary hypertension or Chronic obstructive pulmonary disease (COPD).
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), polycystic ovarian syndrome (PCOS), inborn/ congenital errors of metabolism (e.g. Phenylketonuria (PKU), galactosaemia)
- Active inflammatory bowel disease.
- Acute infection.
- Acute or chronic renal disease.
- Malignancy (or history of malignancy with 5 y).
- Recent (within 6 mo) or current steroid treatment, hormone replacement therapy (HRT), hormonal contraception, or other hormonal therapies that may interfere with outcome measures.
- Coagulopathy.
- Musculoskeletal or neurological disorders.
- Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.
- Amenorrhoea for a reason other than menopause.
- Contraindications for Magnetic Resonance Imaging (MRI).
- Allergy or sensitivity to local anaesthesia, or dressing adhesive.
- Inner ear pathology or vertigo
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06806501